Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 7, 1998, Pages 1620-1628

  Mulato, A S ^a   Lamy, P D ^a   Miller, M D ^a   Li, W X ^a   Anton, K E ^a   Hellmann, N S ^a   Cherrington, J M ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; LAMIVUDINE; PLACEBO; PRODRUG; RITONAVIR; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERM CARE; MAINTENANCE THERAPY; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS CHARACTERIZATION; VIRUS ISOLATION; VIRUS LOAD;

EID: 0031861796     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.7.1620     Document Type: Article

References (53)

1. Balzarini, J., and E. De Clercq. 1991. 5-Phosphoribosyl-1-pyrophosphate synthetase converts the acyclic nucleoside phosphonates 9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and 9-(2-phosphonylmethoxyethyl)adenine directly to their antivirally active diphosphate derivatives. J. Biol. Chem. 266: 8686-8689.
2. Balzarini, J., C. F. Perno, D. Schols, and E. De Clercq. 1991. Activity of acyclic nucleoside phosphonate analogues against human immunodeficiency virus in monocyte/macrophages and peripheral blood lymphocytes. Biochem. Biophys. Res. Commun. 178:329-335.
3. Balzarini, J., Z. Hao, P. Herdewijn, D. G. Johns, and E. DeClerq. 1991. Intracellular metabolism and mechanism of antiretrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. Proc. Natl. Acad. Sci. USA 88:1499-1503.
4. Balzarini, J., A. Holy, J. Jindrich, L. Naesens, R. Snoeck, D. Schols, and E. De Clercq. 1993. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl) derivatives of adenine and 2,6-diaminopurine. Antimicrob. Agents Chemother. 37:332-338.
5. Balzarini, J., J. F. Nave, M. A. Becker, M. Tatiban, and E. DeClercq. 1995. Kinetic properties of adenine nucleotide analogues against purified 5-phosphoribosyl-1-pyrophosphate synthetases from E. coli, rat liver, and human erythrocytes. Nucleosides Nucleotides 14:1861-1871.
6. Boucher, C. A. B., E. O'Sullivan, J. W. Mulder, C. Ramautarsing, P. Kellam, G. Darby, J. M. A. Lange, J. Goudsmit, and B. A. Larder. 1992. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J. Infect. Dis. 165:105-110.
7. Boucher, C. A. B., W. Kuelen, T. Van Bommel, M. Nijhuis, D. De Jong, M. De Jong, P. Schipper, and N. K. T. Back. 1996. Human immunodeficiency virus type 1 drug susceptibility determination using recombinant viruses generated from patient sera tested in a cell-killing assay. Antimicrob. Agents Chemother. 40:2404-2409.
8. Carpenter, C. C. J. et al. 1997. Antiretroviral therapy for HIV infection in 1997. JAMA 277:1962-1969.
9. Cherrington, J. M. Unpublished data.
10. Cherrington, J. M., A. S. Mulato, M. D. Fuller, and M. S. Chen. 1996. Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro. Antimicrob. Agents Chemother. 40:2212-2216.
11. Cherrington, J. M., S. J. W. Allen, N. Bischofberger, and M. S. Chen. 1995. Kinetic interaction of the diphosphates of 9-(2-phosphonylmethoxyethyl)adenine and other anti-HIV active purine congeners with HIV reverse transcriptase and human DNA polymerases α, β, and γ. Antivir. Chem. Chemother. 6:217-221.
12. D'Aquila, R. T., V. A. Johnson, S. L. Wells, A. J. Japour, D. R. Kuritzkes, V. DeGrutotola, P. S. Reichelderfer, R. W. Coombs, C. S. Crumpacker, J. O. Kahn and D. D. Richman, and the AIDS Clinical Trials Group Protocol 116/117 Team and Virology Committee Resistance Working Group. 1995. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann. Intern. Med. 122:401-408.
13. Davey, R. T., Jr., D. G. Chaitt, G. F. Reed, W. W. Freimuth, B. R. Herpin, J. A. Metcalf, P. S. Eastman, J. Falloon, J. A. Kovacs, M. A. Polis, R. E. Walker, H. Masur, J. Boyle, S. Coleman, S. R. Cox, L. Wathen, C. L. Daenzer, and H. C. Lane. 1996. Randomized, controlled phase I/II trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients. Antimicrob. Agents Chemother. 40:1657-1664.
14. De Clercq, E., A. Holy, I. Rosenberg, T. Sakuma, J. Balzarini, and P. C. Maudgal. 1986. A novel selective broad-spectrum anti-DNA virus agent. Nature (London) 323:464-467.
15. De Clercq, E., T. Sakuman, M. Baba, R. Pauwels, J. Balzarini, I. Rosenberg, and A. Holy. 1987. Antiviral activity of phosphonylmethoxyalkyl derivatives of purines and pyrimidines. Antivir. Res. 8:261-272.
16. Deeks, S. G., A. Collier, J. Lalezari, A. Pavia, D. Rodrigue, W. L. Drew, J. Toole, H. S. Jaffe, A. S. Mulato, P. D. Lamy, W. Li, J. M. Cherrington, N. Hellmann, and J. Kahn. 1997. The safety and efficacy of adefovir dipivoxil, a novel anti-HIV therapy, in HIV infected adults. J. Infect. Dis. 176:1517-1523.
17. Demeter, L. M., T. Nawaz, G. Morse, R. Dolin, A. Dexter, P. Gerondelis, and R. C. Reichman. 1995. Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy. J. Infect. Dis. 172: 1480-1485.
18. + cells per cubic millimeter. N. Engl. J. Med. 333:1662-1669.
19. Fitzgibbon, J. E., R. M. Howell, C. A. Haberzettl, S. J. Sperber, D. J. Gocke, and D. T. Dubin. 1992. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine. Antimicrob. Agents Chemother. 36:153-157.
20. Foli, A., K. M. Sogocio, B. Anderson, M. Kavlick, M. W. Saville, M. A. Wainberg, X. Gu, J. M. Cherrington, H. Mitsuya, and R. Yarchoan. 1996. In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA). Antivir. Res. 32:91-98.
21. Gao, Q., Z. Gu, M. A. Parniak, J. Cameron, N. Cammack, C. Boucher, and M. A. Wainberg. 1993. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 37:1390-1392.
22. Gong, Y.-F., D. R. Marshall, R. V. Srinivas, and A. Fridland. 1994. Susceptibilities of zidovudine-resistant variants of human immunodeficiency virus type 1 to inhibition by acyclic nucleoside phosphonates. Antimicrob. Agents Chemother. 38:1683-1687.
23. Gu, Z., Q. Gao, H. Fang, H. Salomon, M. A. Parniak, E. Goldberg, J. Cameron, and M. A. Wainberg. 1994. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 38:275-281.
24. Gu, Z., H. Salomon, J. M. Cherrington, A. S. Mulato, M. S. Chen, R. Yarchoan, A. Foli, K. Sogocio, and M. A. Wainberg. 1995. K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine. Antimicrob. Agents Chemother. 39:1888-1891.
25. Holodniy, M., L. Mole, D. Margolis, J. Moss, H. Dong, E. Boyer, M. Urdea, J. Kolberg, and S. Eastman. 1995. Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy. J. Virol. 69:3510-3516.
26. Holodniy, M., D. Katzenstein, L. Mole, M. Winters, and T. Merigan. 1996. Human immunodeficiency virus reverse transcriptase codon 215 mutations diminish virologic response to didanosine-zidovudine therapy in subjects with non-syncytium-inducing phenotype. J. Infect. Dis. 174:854-857.
27. Hooker, D. J., G. Tachedjian, A. E. Solomon, A. D. Gurusinghe, S. Land, C. Birch, J. L. Anderson, B. M. Roy, E. Arnold, and N. J. Deacon. 1996. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3′-azido-3′-deoxythymidine. J. Virol. 70:8010-8018.
28. Kellam, P., C. A. B. Boucher, and B. A. Larder. 1992. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Natl. Acad. Sci. USA 89:1934-1938.
29. Kellam, P., C. A. Boucher, J. M. Tijnagel, and B. A. Larder. 1994. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. J. Gen. Virol. 75:341-351.
30. Kozal, M. J., K. Kroodsma, M. A. Winters, R. W. Shafer, B. Efron, D. A. Katzenstein, and T. C. Merigan. 1994. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Ann. Intern. Med. 121:263-268.
31. Lacey, S. F., and B. A. Larder. 1994. A novel mutation (V75T) in the HIV-1 reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3′-dideoxythymidine (D4T) in cell culture. Antimicrob. Agents Chemother. 38:1428-1432.
32. Larder, B. A., A. G. Darby, and D. D. Richman. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734.
33. Larder, B. A., and S. D. Kemp. 1989. Multiple mutation in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1158.
34. Lin, P.-F., H. Samanta, R. E. Rose, A. K. Patick, J. Trimble, C. M. Bechtold, D. R. Revie, N. C. Khan, M. E. Federici, H. Li, A. Lee, R. E. Anderson, and R. J. Colonno. 1994. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J. Infect. Dis. 170:1157-1164.
35. Mayers, D. L., D. L. Gallahan, G. J. Martin, W. W. Emmons, R. C. Y. Chung, K. M. Spooner, J. A. Newton, N. E. Aronson, and O. S. Weislow. 1997. Drug resistance genotypes from plasma virus of HIV-infected patients failing combination drug therapy, abstr. 81. In Abstracts of the International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication.
36. Nijhuis, M., R. Schuurman, D. De Jong, R. Van Leeuwen, J. Lange, S. Danner, W. Keulen, T. De Groot, and C. A. B. Boucher. 1997. Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. J. Infect. Dis. 176:398-405.
37. Pauwels, R., J. Balzarini, D. Schols, M. Baba, J. Desmyter, I. Rosenberg, A. Holy, and E. De Clercq. 1988. Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob. Agents Chemother. 32:1025-1030.
38. Perno, C. F., E. Balestra, S. Aquaro, S. Panti, A. Cenci, G. Lazzarino, B. Tavazzi, D. Di Pierro, J. Balzarini, and R. Calio. 1996. Potent inhibition of human immunodeficiency and herpes simplex virus type 1 by 9-(2-phosphonylmethoxyethyl)adenine in primary macrophages is determined by drug metabolism, nucleotide pools, and cytokines. Mol. Pharmacol. 50:359-366.
39. Robbins, B. L., J. Greenhaw, M. C. Connelly, and A. Fridland. 1995. Metabolic pathways for activation of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in human lymphoid cells. Antimicrob. Agents Chemother. 39:2304-2308.
40. Rooke, R., M. Tremblay, H. Soudeyns, L. DeStephano, X.-J. Yao, M. Fanning, J. S. G. Montaner, M. O'Shaughnessy, K. Gelmon, C. Tsoukas, H. Ruedy, and M. A. Wainberg. 1989. Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine (AZT) therapy. AIDS 3:411-415.
41. Schinazi, R. F., R. J. Lloyd, M. H. Nguyen, D. L. Cannon, A. McMillan, N. Ilksoy, C. K. Chu, D. C. Liotta, H. Z. Bazmi, and J. W. Mellors. 1993. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother. 37:875-881.
42. Schmit, J.-C., J. Cogniaux, P. Hermans, C. Van Vaeck, S. Sprecher, B. Van Remoortel, M. Witvrouw, J. Balzarini, J. Desmyter, E. De Clercq, and A.-M. Vandamme. 1996. Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. J. Infect. Dis. 174:962-968.
43. Schuurman, R., M. Nijhuis, R. Van Leeuwen, P. Schipper, D. De Jong, P. Collis, S. A. Danner, J. Mulder, C. Loveday, C. Christopherson, S. Kwok, J. Sninsky, and C. A. B. Boucher. 1995. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect. Dis. 171:1411-1419.
44. Shafer, R. W., A. K. N. Iversen, M. A. Winters, E. Aguiniga, D. A. Katzenstein, T. C. Merigan, and the AIDS Clinical Trials Group 143 Virology Team. 1995. Drug resistance and heterogenous long-term virologie responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. J. Infect. Dis. 172:170-178.
45. Shafer, R. W., D. J. Levee, M. A. Winters, K. L. Richmond, D. Huang, and T. C. Merigan. 1997 Comparison of QIAamp HCV kit spin columns, silica beads, and phenol-chloroform for recovering human immunodeficiency virus type 1 RNA from plasma. J. Clin. Microbiol. 35:520-522.
46. Shirasaka, T., S. Chokekijchai, A. Yamada, G. Gosselin, J. L. Imbach, and H. Mitsuya. 1995. Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells. Antimicrob. Agents Chemother. 39: 2555-2559.
47. Shirasaka, T., M. F. Kavlick, T. Ueno, W.-Y. Gao, E. Kojima, M. L. Alcaide, S. Chokekijchai, B. M. Roy, E. Arnold, R. Yarchoan, and H. Mitsuya. 1995. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. USA 92:2398-2402.
48. St. Clair M. H., J. L. Martin, G. Tudor-Williams, M. C. Bach, C. I. Vavro, D. M. King, P. Kellam, S. D. Kemp, and B. A. Larder. 1991. Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253:1557-1559.
49. Tanaka, M., R. V. Srinivas, T. Ueno, M. F. Kavlick, F. K. Hui, A. Fridland, J. S. Driscoll and H. Mitsuya. 1997. In vitro induction of human immunodeficiency virus type 1 variants resistant to 2′-β-fluoro-2′,3′-dideoxyadenosine. Antimicrob. Agents Chemother. 41:1313-1318.
50. Wainberg, M. A., H. Salomon, Z. Gu, J. S. G. Montaner, T. P. Cooley, R. McCaffrey, J. Ruedy, H. M. Hirst, N. Cammack, J. Cameron, and W. Nicholson. 1995. Development of HIV-1 resistance to (-)2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 9: 351-357.
51. Wainberg, M. A., W. C. Drosopoulos, H. Salomon, M. Hsu, G. Borkow, M. A. Parniak, Z. Gu, Q. Song, J. Manne, S. Islam, G. Castriota, and V. R. Prasad. 1995. Enhanced fidelity of 3TC-selcctcd mutant HIV-1 reverse transcriptase. Science 271:1282-1284.
52. Winters, M. A., R. W. Shafer, R. A. Jellinger, G. Mamtora, T. Gingeras, and T. C. Merigan 1997. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob. Agents Chemother. 41:757-762.
53. Zhang, D., A. M. Caliendo, J. J. Eron, K. M. DeVore, J. C. Kaplan, M. S. Hirsch, and R. T. D'Aquila. 1994. Resistance to 2′,3′-dideoxyctyidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 38:282-287.